Addex Therapeutics logo
Addex Therapeutics
ADXN | NASDAQ
Chart Builder DCF Calculator
$3.83
-$0.23 (-5.67%)
At close: Nov 16, 2026, 4:00 PM ET
$3.72
-$0.11 (-2.87%)
After-hours: Nov 16, 2026, 7:27 PM ET

Addex Therapeutics Company Profile

Company profile explained

Company Profile

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

Key Executives

Name Position
Timothy Mark Dyer Co-Founder, Chief Executive Officer & Director
Jean-Philippe Rocher Head of Pharmaceutical Development & Member of Executive Management
Lénaic Teyssédou Head of Finance
Mikhail Kalinichev Head of Translational Science
Roger G. Mills Chief Medical Officer & Director

Latest SEC Filings

Date Type Title
Oct 29, 2026 6-K Filing
Oct 08, 2026 6-K Filing
Oct 02, 2026 6-K Filing
Sep 28, 2026 6-K Filing
Sep 25, 2026 6-K Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
View All SEC Filings ➞
Addex Therapeutics
Addex Therapeutics logo
Country Switzerland
IPO Date Feb 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Timothy Mark Dyer

Contact Details

Chemin des Mines, 9 Geneva, GE 1202 Switzerland

Stock Details

Ticker Symbol ADXN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574232
CUSIP Number 00654J206
ISIN Number US00654J2069
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.